Cellectar Biosciences, Inc. — Regulatory Filings 2016

Oct 5, 2016

8-K 1 v450004_8k.htm FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

---

FORM 8-K

---

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report: October 4, 2016 ( Date of earliest event reported )

CELLECTAR BIOSCIENCES, INC. ( Exact name of registrant as specified in its charter )

Delaware	1-36598	04-3321804
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)

3301 Agriculture Drive Madison, WI 53716 ( Address of principal executive offices )

(608) 441-8120 ( Registrant's telephone number, including area code )

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Field: Page; Sequence: 1

Field: /Page

ITEM 7.01 REGULATION FD DISCLOSURE

On October 4, 2016, we issued a press release announcing that the United States Patent and Trademark Office issued a formal patent allowance for CLR 1603, which covers method of use for the treatment of a variety of solid tumors and associated cancer stem cells using the company’s phospholipid drug conjugate (“PDC”) delivery platform technology with paclitaxel. A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits

Number	Title
99.1	Press release dated October 4, 2016, entitled “Cellectar Biosciences Announces USPTO Issues Formal Patent Allowance for CLR 1603”

Field: Page; Sequence: 2; Options: NewSection; Value: 2

2

Field: /Page

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 5, 2016
By:	/s/ Chad J. Kolean
	Name: Chad J. Kolean
	Title: Vice President and Chief Financial Officer

Field: Page; Sequence: 3; Value: 2

3

Field: /Page

EXHIBIT INDEX

Number	Title
99.1	Press release dated October 4, 2016, entitled “Cellectar Biosciences Announces USPTO Issues Formal Patent Allowance for CLR 1603”

Field: Page; Sequence: 4; Options: Last

4

Field: /Page